- Home
- LAB vs GOSS Comparison
LAB vs GOSS Comparison
Compare LAB & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAB
- GOSS
- Stock Information
- Founded
- LAB 1999
- GOSS 2015
- Country
- LAB United States
- GOSS United States
- Employees
- LAB N/A
- GOSS N/A
- Industry
- LAB Biotechnology: Laboratory Analytical Instruments
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- LAB Industrials
- GOSS Health Care
- Exchange
- LAB Nasdaq
- GOSS Nasdaq
- Market Cap
- LAB 504.2M
- GOSS 501.2M
- IPO Year
- LAB 2011
- GOSS 2019
- Fundamental
- Price
- LAB $1.24
- GOSS $2.39
- Analyst Decision
- LAB Buy
- GOSS Strong Buy
- Analyst Count
- LAB 2
- GOSS 6
- Target Price
- LAB $2.50
- GOSS $8.60
- AVG Volume (30 Days)
- LAB 1.6M
- GOSS 2.9M
- Earning Date
- LAB 11-04-2025
- GOSS 11-03-2025
- Dividend Yield
- LAB N/A
- GOSS N/A
- EPS Growth
- LAB N/A
- GOSS N/A
- EPS
- LAB N/A
- GOSS N/A
- Revenue
- LAB $172,271,000.00
- GOSS $40,237,000.00
- Revenue This Year
- LAB N/A
- GOSS N/A
- Revenue Next Year
- LAB N/A
- GOSS $16.11
- P/E Ratio
- LAB N/A
- GOSS N/A
- Revenue Growth
- LAB 76.33
- GOSS N/A
- 52 Week Low
- LAB $0.92
- GOSS $0.66
- 52 Week High
- LAB $2.32
- GOSS $3.60
- Technical
- Relative Strength Index (RSI)
- LAB 45.85
- GOSS 48.38
- Support Level
- LAB $1.12
- GOSS $2.28
- Resistance Level
- LAB $1.25
- GOSS $2.52
- Average True Range (ATR)
- LAB 0.09
- GOSS 0.15
- MACD
- LAB -0.01
- GOSS 0.02
- Stochastic Oscillator
- LAB 34.29
- GOSS 67.44
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.